⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9694838 | 1.00 | — | — | |
| SCHEMBL2675782 | 1.00 | — | — | |
| SCHEMBL679489 | 1.00 | — | — | |
| SCHEMBL7804 | 1.00 | — | — | |
| SCHEMBL8015149 | 1.00 | — | — | |
| SCHEMBL8661925 | 1.00 | — | — | |
| SCHEMBL131783 | 1.00 | — | — | |
| SCHEMBL21774 | 1.00 | — | — | |
| SCHEMBL8420181 | 1.00 | — | — | |
| SCHEMBL11234658 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115598-A1 | Methods for Treatment of Alport Syndrome | SANOFI (FR) | 2024-04-11 | — | — | US | disclosed |
| WO-2024076934-A2 | COMPOSITIONS AND METHODS FOR MODULATION OF CFTR | CYSTIC FIBROSIS FOUNDATION (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024026122-A2 | COMPOUNDS FOR TREATMENT OF CONDITIONS AND DISEASES | STOKE THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230116704-A1 | ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES | STOKE THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20220133769-A1 | Methods for Treatment of Alport Syndrome | SANOFI (FR) | 2022-05-05 | — | — | US | disclosed |
| WO-2021113541-A1 | ANTISENSE OLIGOMERS FOR TREATMENT OF CONDITIONS AND DISEASES | STOKE THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210100828-A1 | Methods for Treatment of Alport Syndrome | SANOFI (FR) | 2021-04-08 | — | — | US | disclosed |
| EP-3618838-A1 | METHODS FOR TREATMENT OF ALPORT SYNDROME | Sanofi (FR) | 2020-03-11 | — | — | EP | disclosed |
| CN-110740737-A | Methods for treating Alport syndrome | 赛诺菲 | 2020-01-31 | — | — | CN | disclosed |
| WO-2018204788-A1 | METHODS FOR TREATMENT OF ALPORT SYNDROME | Regulus Therapeutics Inc. (US) | 2018-11-08 | — | — | WO | disclosed |
| EP-2249873-B1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS | PASTEUR INSTITUT (FR) | 2016-11-16 | — | — | EP | disclosed |
| US-9295730-B2 | Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanion for the treatment of AIDS | INSTITUT PASTEUR (FR) | 2016-03-29 | — | — | US | disclosed |
| US-20110105412-A1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS | UNIVERSITE PARIS-SUD (FR) | 2011-05-05 | — | — | US | disclosed |
| EP-2249873-A2 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS | Institut Pasteur (FR) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009098147-A2 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO A POLYANION FOR THE TREATMENT OF AIDS | INSTITUT PASTEUR (FR) | 2009-08-13 | — | — | WO | disclosed |
| EP-2087911-A1 | Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanion for the treatment of AIDS | INSTITUT PASTEUR (FR) | 2009-08-12 | — | — | EP | disclosed |
| US-4407796-A | IMMUNOLOGY | AMERICAN CYANAMID COMPANY (US) | 1983-10-04 | — | — | US | disclosed |
| EP-0082927-A1 | Salts of polyhexaose sulfate derivatives as modulators of the complement system | AMERICAN CYANAMID COMPANY (US) | 1983-07-06 | — | — | EP | disclosed |